Our contribution to UN Sustainable Development Goals
Oriola is committed to the United Nations Sustainable Development Goals (SDGs), and our sustainability strategy is aligned with them. SDGs are a global action plan to end poverty, protect the planet and ensure that all people enjoy peace and prosperity by 2030. Out of 17 goals, we have identified following four goals where our contribution is the most significant.
Oriola secures availability and equal access to medicines by distributing almost half of all pharmaceuticals used in Finland and Sweden. In Sweden, we also distribute the majority of all vaccines. Our dose-dispensing, patient support and medical information services promote safe medicine usage. Our Real World Evidence (RWE) studies contribute to data-driven decision-making in healthcare and the development of effective pharmacotherapy.
Read more about our role in society
Oriola is a fair and equal workplace that supports diversity. We do not approve discrimination in any form. Our Code of Conduct outlines the principles with which all our employees and businesses are expected to comply. Oriola also has an anonymous reporting channel, and we encourage all our employees to report misconduct, or conduct that does not accord with our values. We promote sustainable business practices in our supplier network through our Business Partner Code of Conduct and systematic supplier evaluation and assessments.
We support equal employment opportunities and select employees based on their suitability for the task and professional skills. For example, we annually conduct a salary review to ensure that there are no unexplained pay gaps. The health and safety of our employees is our priority, and we have a low occupational injury rate.
Oriola’s mission is to provide sustainable products and services, and our goal is to increase sustainable health and wellbeing products in our own brands. Through systematic environmental management, we aim to minimise the environmental impacts of our operations. We are continuously working to increase our recycling and minimise waste production in our operations. We also actively take part in various initiatives in the pharmaceutical sector that aim to support sustainable consumption.
Read more about our sustainability management
Our goal is to achieve carbon neutrality by 2030. As part of this goal, we are committed to achieve carbon neutrality in our own operations by 2025. This means reducing to zero CO2 emissions from sources owned by the company and purchased energy. We have calculated our carbon footprint in accordance with the Greenhouse Gas Protocol accounting principles, and it covers the whole company. As an intermediate target, we are aiming to use only renewable electricity and carbon-neutral heat by the end of 2023, and we systematically increase their share.
Read more about our carbon footprint